α-hydrazino-β-3,4-dihydroxyphenylpropionic acid | 41670-34-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-hydrazino-β-3,4-dihydroxyphenylpropionic acid
• 英文别名: 3-(3,4-Dihydroxyphenyl)-2-hydrazinylpropanoic acid
• CAS: 41670-34-2
• 化学式: C₉H₁₂N₂O₄
• 分子量: 212.205
• InChiKey: ZUQASNHJHJYLPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  116
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• [EN] AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE<br/>[FR] ANALOGUES DE L'AFMT ET LEUR UTILISATION DANS DES MÉTHODES DE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：HARVARD COLLEGE

  公开号：WO2021216781A1

  公开（公告）日：2021-10-28

  The present disclosure provides compounds of formula (I), (II), and (la): Methods of preparing these molecules and their use for treatment of Parkinson's Disease are described.

  本公开提供了式(I)、(II)和(la)的化合物：描述了制备这些分子的方法以及它们用于治疗帕金森病的用途。
• SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION
  申请人：The Regents of the University of California

  公开号：EP3876871A1

  公开（公告）日：2021-09-15
• Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
  申请人：NEURODERM, LTD.

  公开号：US20130253056A1

  公开（公告）日：2013-09-26

  Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof.
• Pulmonary Delivery for Levodopa
  申请人：Civitas Therapeutics, Inc.

  公开号：US20180055800A1

  公开（公告）日：2018-03-01

  In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
• METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS
  申请人：Tufts Medical Center, Inc.

  公开号：US20210220298A1

  公开（公告）日：2021-07-22

  The invention provides methods and compositions for use in the prevention and treatment of antipsychotic medication-induced metabolic syndrome (MetS) and diseases and conditions related to MetS.